Physician profile
Robin A Watson
NPI 1508820507
$648.53
in general payments reported to CMS, 2019-2025
14 companies · $179 in 2025
The $179 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $17.70 · 2023: $194 · 2024: $258 · 2025: $179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $631.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $630.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $167.69 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| E.R. Squibb & Sons, L.L.C. | $128.25 | 2024 | Cobenfy |
| Boston Scientific Corporation | $58.47 | 2023 | |
| Amgen INC. | $49.12 | 2023 | Repatha, Otezla |
| Astellas Pharma US INC | $44.56 | 2024-2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $43.73 | 2023-2024 | Airsupra, Farxiga |
| Abbvie INC. | $36.33 | 2022-2024 | |
| Inspire Medical Systems, INC. | $19.46 | 2024 | Inspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.20 | 2023 | Jardiance |
| Vertex Pharmaceuticals Incorporated | $18.44 | 2025 | |
| Glaxosmithkline, LLC. | $17.91 | 2023 | Arexvy |
| Lilly USA, LLC | $16.41 | 2023 | Mounjaro |
| Exact Sciences Corporation | $15.36 | 2025 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.60 | 2024 | Caplyta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Watson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.